Spotlight on Urology

Ulka Vaishampayan, MD
Credits: 1.0 CNE
Nursing Considerations for Navigating the Advanced Prostate Cancer Disease Continuum in the Management of mHSPC, DNA repair deficiency mCRPC, and nmCRPC
Ulka Vaishampayan, MD
SUNA

Nursing Considerations for Navigating the Advanced Prostate Cancer Disease Continuum in the Management of mHSPC, DNA repair deficiency mCRPC, and nmCRPC

Start

Activity Details

Free CNE
1.0 ANCC contact hour
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

The Society of Urologic Nurses and Associates (SUNA)

Target Audience

This activity is designed to meet the educational needs of nurses, NPs, and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  2. Assess evolving treatment strategies for patients with mHSPC and nmCRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
  3. Implement best practice strategies to minimize or manage disease and treatment-associated complications to improve quality of life

Activity Description

This activity is designed to help nurses understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient management.

Statement of Educational Need

Nurses play a central role in educating and guiding advanced prostate cancer patients who need to make treatment decisions. However, with the rapidly expanding number of therapeutic options and evolving treatment plans, nurses find it challenging to stay up-to-date on the latest clinical data. As research provides more information regarding sequencing strategies, nurses will need to understand the rationale behind these decisions. Each of these available agents differs in its mechanisms of action, as well as its impact on disease and patient outcomes. Nurses require familiarity with the side effects, drug interactions, and complications associated with these new agents.

Faculty

Ulka Vaishampayan, MD
Chair of Phase I therapy
GU Medical Oncology
Professor Internal Medicine
University of Michigan
Ann Arbor, MI

Disclosures
Honoraria: Sanofi, Bayer, Pfizer
Consulting fees: Bayer, Pfizer

Accreditation Statement

The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is an approved provider of nursing continuing professional development by the California Board of Registered Nursing, Provider Number CEP5556.

1.0 contact hour is awarded for this NCPD activity.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Support Acknowledgement

This activity is supported by a medical education grant from Astellas and Pfizer, Inc., AstraZeneca, and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

SUNA and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, SUNA identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by SUNA to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SUNA is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CNE
1.0 ANCC contact hour
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

The Society of Urologic Nurses and Associates (SUNA)

Target Audience

This activity is designed to meet the educational needs of nurses, NPs, and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  2. Assess evolving treatment strategies for patients with mHSPC and nmCRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
  3. Implement best practice strategies to minimize or manage disease and treatment-associated complications to improve quality of life

Activity Description

This activity is designed to help nurses understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient management.

Statement of Educational Need

Nurses play a central role in educating and guiding advanced prostate cancer patients who need to make treatment decisions. However, with the rapidly expanding number of therapeutic options and evolving treatment plans, nurses find it challenging to stay up-to-date on the latest clinical data. As research provides more information regarding sequencing strategies, nurses will need to understand the rationale behind these decisions. Each of these available agents differs in its mechanisms of action, as well as its impact on disease and patient outcomes. Nurses require familiarity with the side effects, drug interactions, and complications associated with these new agents.

Faculty

Ulka Vaishampayan, MD
Chair of Phase I therapy
GU Medical Oncology
Professor Internal Medicine
University of Michigan
Ann Arbor, MI

Disclosures
Honoraria: Sanofi, Bayer, Pfizer
Consulting fees: Bayer, Pfizer

Accreditation Statement

The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is an approved provider of nursing continuing professional development by the California Board of Registered Nursing, Provider Number CEP5556.

1.0 contact hour is awarded for this NCPD activity.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Support Acknowledgement

This activity is supported by a medical education grant from Astellas and Pfizer, Inc., AstraZeneca, and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

SUNA and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, SUNA identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by SUNA to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SUNA is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Urology Presentations

Ulka Vaishampayan, MD
1.0 CNE
SUNA
Nursing Considerations for Navigating the Advanced Prostate Cancer Disease Continuum in the Management of mHSPC, DNA repair deficiency mCRPC, and nmCRPC

Nursing Considerations for Navigating the Advanced Prostate Cancer Disease Continuum in the Management of mHSPC, DNA repair deficiency mCRPC, and nmCRPC

Start

Activity Details

Free CNE
1.0 ANCC contact hour
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

The Society of Urologic Nurses and Associates (SUNA)

Target Audience

This activity is designed to meet the educational needs of nurses, NPs, and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  2. Assess evolving treatment strategies for patients with mHSPC and nmCRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
  3. Implement best practice strategies to minimize or manage disease and treatment-associated complications to improve quality of life

Activity Description

This activity is designed to help nurses understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient management.

Statement of Educational Need

Nurses play a central role in educating and guiding advanced prostate cancer patients who need to make treatment decisions. However, with the rapidly expanding number of therapeutic options and evolving treatment plans, nurses find it challenging to stay up-to-date on the latest clinical data. As research provides more information regarding sequencing strategies, nurses will need to understand the rationale behind these decisions. Each of these available agents differs in its mechanisms of action, as well as its impact on disease and patient outcomes. Nurses require familiarity with the side effects, drug interactions, and complications associated with these new agents.

Faculty

Ulka Vaishampayan, MD
Chair of Phase I therapy
GU Medical Oncology
Professor Internal Medicine
University of Michigan
Ann Arbor, MI

Disclosures
Honoraria: Sanofi, Bayer, Pfizer
Consulting fees: Bayer, Pfizer

Accreditation Statement

The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is an approved provider of nursing continuing professional development by the California Board of Registered Nursing, Provider Number CEP5556.

1.0 contact hour is awarded for this NCPD activity.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Support Acknowledgement

This activity is supported by a medical education grant from Astellas and Pfizer, Inc., AstraZeneca, and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

SUNA and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, SUNA identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by SUNA to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SUNA is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CNE
1.0 ANCC contact hour
Released: February 22, 2022
Expires: February 21, 2023
60 minutes to complete

Accredited By

The Society of Urologic Nurses and Associates (SUNA)

Target Audience

This activity is designed to meet the educational needs of nurses, NPs, and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  2. Assess evolving treatment strategies for patients with mHSPC and nmCRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
  3. Implement best practice strategies to minimize or manage disease and treatment-associated complications to improve quality of life

Activity Description

This activity is designed to help nurses understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient management.

Statement of Educational Need

Nurses play a central role in educating and guiding advanced prostate cancer patients who need to make treatment decisions. However, with the rapidly expanding number of therapeutic options and evolving treatment plans, nurses find it challenging to stay up-to-date on the latest clinical data. As research provides more information regarding sequencing strategies, nurses will need to understand the rationale behind these decisions. Each of these available agents differs in its mechanisms of action, as well as its impact on disease and patient outcomes. Nurses require familiarity with the side effects, drug interactions, and complications associated with these new agents.

Faculty

Ulka Vaishampayan, MD
Chair of Phase I therapy
GU Medical Oncology
Professor Internal Medicine
University of Michigan
Ann Arbor, MI

Disclosures
Honoraria: Sanofi, Bayer, Pfizer
Consulting fees: Bayer, Pfizer

Accreditation Statement

The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is an approved provider of nursing continuing professional development by the California Board of Registered Nursing, Provider Number CEP5556.

1.0 contact hour is awarded for this NCPD activity.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Support Acknowledgement

This activity is supported by a medical education grant from Astellas and Pfizer, Inc., AstraZeneca, and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

SUNA and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, SUNA identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by SUNA to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SUNA is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com